Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans

Stephen J. Heishman, Jack E. Henningfield

Research output: Contribution to journalArticle

Abstract

Eight male community volunteers, who reported current psychomotor stimulant use, were trained to discriminate between the presence and absence of orally administered d-amphetamine 30 mg. During daily experimental sessions, in which a single drug dose or placebo was tested, physiological and subjective measures were assessed and subjects indicated their discrimination by responding on an operant color-tracking procedure. During four test of acquisition sessions, discriminative responding indicated that all subjects learned the discrimination, and d-amphetamine produced physiological and subjective effects typical of psychomotor stimulants. Generalization testing then followed in which dose-response curves were determined for the following drugs:d-amphetamine (3.75, 7.5, 15 and 30 mg), diazepam (5, 10, 20 and 40 mg), and methylphenidate (7.5, 15, 30 and 60 mg). d-Amphetamine and methylphenidate produced dose-related increases in d-amphetamine-appropriate responding, whereas no dose of diazepam substituted for d-amphetamine in any subject. d-Amphetamine and methylphenidate produced a similar pattern of subjective changes, including increased ratings of euphoria and drug liking and decreased sedation. In contrast, diazepam increased subjective scales of sedation and dysphoria. These results are consistent with similar studies testing animals and humans and demonstrate the utility of human drug discrimination research as an integral component of drug abuse liability testing.

Original languageEnglish (US)
Pages (from-to)436-442
Number of pages7
JournalPsychopharmacology
Volume103
Issue number4
DOIs
StatePublished - Apr 1991
Externally publishedYes

Fingerprint

Dextroamphetamine
Methylphenidate
Diazepam
Pharmaceutical Preparations
Substance Abuse Detection
Volunteers
Color
Placebos
Research

Keywords

  • d-Amphetamine
  • Diazepam
  • Drug abuse
  • Human drug discrimination
  • Methylphenidate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. / Heishman, Stephen J.; Henningfield, Jack E.

In: Psychopharmacology, Vol. 103, No. 4, 04.1991, p. 436-442.

Research output: Contribution to journalArticle

Heishman, Stephen J. ; Henningfield, Jack E. / Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. In: Psychopharmacology. 1991 ; Vol. 103, No. 4. pp. 436-442.
@article{3dbcf1f2ea1d4d348bb75a78be5c3b14,
title = "Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans",
abstract = "Eight male community volunteers, who reported current psychomotor stimulant use, were trained to discriminate between the presence and absence of orally administered d-amphetamine 30 mg. During daily experimental sessions, in which a single drug dose or placebo was tested, physiological and subjective measures were assessed and subjects indicated their discrimination by responding on an operant color-tracking procedure. During four test of acquisition sessions, discriminative responding indicated that all subjects learned the discrimination, and d-amphetamine produced physiological and subjective effects typical of psychomotor stimulants. Generalization testing then followed in which dose-response curves were determined for the following drugs:d-amphetamine (3.75, 7.5, 15 and 30 mg), diazepam (5, 10, 20 and 40 mg), and methylphenidate (7.5, 15, 30 and 60 mg). d-Amphetamine and methylphenidate produced dose-related increases in d-amphetamine-appropriate responding, whereas no dose of diazepam substituted for d-amphetamine in any subject. d-Amphetamine and methylphenidate produced a similar pattern of subjective changes, including increased ratings of euphoria and drug liking and decreased sedation. In contrast, diazepam increased subjective scales of sedation and dysphoria. These results are consistent with similar studies testing animals and humans and demonstrate the utility of human drug discrimination research as an integral component of drug abuse liability testing.",
keywords = "d-Amphetamine, Diazepam, Drug abuse, Human drug discrimination, Methylphenidate",
author = "Heishman, {Stephen J.} and Henningfield, {Jack E.}",
year = "1991",
month = "4",
doi = "10.1007/BF02244241",
language = "English (US)",
volume = "103",
pages = "436--442",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans

AU - Heishman, Stephen J.

AU - Henningfield, Jack E.

PY - 1991/4

Y1 - 1991/4

N2 - Eight male community volunteers, who reported current psychomotor stimulant use, were trained to discriminate between the presence and absence of orally administered d-amphetamine 30 mg. During daily experimental sessions, in which a single drug dose or placebo was tested, physiological and subjective measures were assessed and subjects indicated their discrimination by responding on an operant color-tracking procedure. During four test of acquisition sessions, discriminative responding indicated that all subjects learned the discrimination, and d-amphetamine produced physiological and subjective effects typical of psychomotor stimulants. Generalization testing then followed in which dose-response curves were determined for the following drugs:d-amphetamine (3.75, 7.5, 15 and 30 mg), diazepam (5, 10, 20 and 40 mg), and methylphenidate (7.5, 15, 30 and 60 mg). d-Amphetamine and methylphenidate produced dose-related increases in d-amphetamine-appropriate responding, whereas no dose of diazepam substituted for d-amphetamine in any subject. d-Amphetamine and methylphenidate produced a similar pattern of subjective changes, including increased ratings of euphoria and drug liking and decreased sedation. In contrast, diazepam increased subjective scales of sedation and dysphoria. These results are consistent with similar studies testing animals and humans and demonstrate the utility of human drug discrimination research as an integral component of drug abuse liability testing.

AB - Eight male community volunteers, who reported current psychomotor stimulant use, were trained to discriminate between the presence and absence of orally administered d-amphetamine 30 mg. During daily experimental sessions, in which a single drug dose or placebo was tested, physiological and subjective measures were assessed and subjects indicated their discrimination by responding on an operant color-tracking procedure. During four test of acquisition sessions, discriminative responding indicated that all subjects learned the discrimination, and d-amphetamine produced physiological and subjective effects typical of psychomotor stimulants. Generalization testing then followed in which dose-response curves were determined for the following drugs:d-amphetamine (3.75, 7.5, 15 and 30 mg), diazepam (5, 10, 20 and 40 mg), and methylphenidate (7.5, 15, 30 and 60 mg). d-Amphetamine and methylphenidate produced dose-related increases in d-amphetamine-appropriate responding, whereas no dose of diazepam substituted for d-amphetamine in any subject. d-Amphetamine and methylphenidate produced a similar pattern of subjective changes, including increased ratings of euphoria and drug liking and decreased sedation. In contrast, diazepam increased subjective scales of sedation and dysphoria. These results are consistent with similar studies testing animals and humans and demonstrate the utility of human drug discrimination research as an integral component of drug abuse liability testing.

KW - d-Amphetamine

KW - Diazepam

KW - Drug abuse

KW - Human drug discrimination

KW - Methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=0026098855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026098855&partnerID=8YFLogxK

U2 - 10.1007/BF02244241

DO - 10.1007/BF02244241

M3 - Article

C2 - 2062984

AN - SCOPUS:0026098855

VL - 103

SP - 436

EP - 442

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -